[ad_1] The Dental and Pharmaceutical Benefit Office (TLV) has decided to extend the Xeljanz (tofacitinib) subsidy to the indications for psoriatic arthritis and ulcerative colitis.1. This decision means that even these patient …
Read More »Decision TLV: Extension of the grant for Xeljanz, now also for …
